Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVAMERS- S may serve for further development of an emergency vaccine against MERS-CoV.

dx.doi.org/10.1128/JVI.01672-13, hdl.handle.net/1765/68656
Journal of Virology
Department of Virology

Song, F, Fux, R, Provacia, L.B.V, Volz, A, Eickmann, M, Becker, S, … Suttera, G. (2013). Middle east respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies. Journal of Virology, 87(21), 11950–11954. doi:10.1128/JVI.01672-13